|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Virginia Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing VirginiaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
HemoShear, LLC
| | | Phone: | (434) 872-0196 | Fax: | (434) 872-0199 | Year Established: | 2008 | Employees: | 30 | Main Contact: | Jim Powers, Chairman & CEO | | Other Contacts: | Robert A. Figler, Ph.D., Scientific Director Paul W. Orange, Head of Operations Nicole Hastings, Ph.D., Director of Scientific Studies Aric Holsinger, CPA, CFO John Reardon, PhD, Head, R&D Brian Wamhoff, PhD, Co-founder & Head of Innovation
| | Company Description | HemoShear works in close partnerships with pharmaceutical and other companies to test and explore in the laboratory the effects of new drug compounds and other chemicals on humans. Their proprietary technology provides the world's only validated, cell-based human surrogate models of organ systems that can predict effects on the human body at early stages in the drug development cycle.
The company's human surrogate technology is based upon the principal that shear stress forces from blood flow are necessary survival factors for human cells. HemoShear's technology imposes human-derived hemodynamic (blood flow) forces on human primary cells to recreate their human biology. Their proof of concept studies demonstrate that HemoShear's technology is far more predictive of human responses than traditional cell culture and animal testing.
HemoShear's technology accelerates drug R&D and reduces costly failures by providing the world's most physiologically relevant environments for discovering and assessing new drug candidates. | |
|
|
|
|
|